1-2 of 2
Yanping Luo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A105: Phase 2 trials of linifanib (ABT‐869) in advanced hepatocellular, renal cell and non‐small cell lung cancer: Associations of response by CT or DCE‐MRI with patient outcome

Free
Han Chong Toh, Wei Peng Yong, Yu‐Ning Wong, Eng‐Huat tan, Christian K. Kollmannsberger, Viswanath Devanarayan, Ke Zhang, Yanping Luo, Daniel Chen, Edward Ashton, Justin L. Ricker, Dawn Carlson, Pei‐Jer Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A105.
https://doi.org/10.1158/1535-7163.TARG-09-A105
Published: 10 December 2009
View article titled, Abstract A105: Phase 2 trials of linifanib (ABT‐869) in advanced hepatocellular, renal cell and non‐small cell lung cancer: Associations of response by CT or DCE‐MRI with patient outcome
Journal Articles

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

Free
Daniel H. Albert, Paul Tapang, Terrance J. Magoc, Lori J. Pease, David R. Reuter, Ru-Qi Wei, Junling Li, Jun Guo, Peter F. Bousquet, Nayereh S. Ghoreishi-Haack, Baole Wang, Gail T. Bukofzer, Yi-Chun Wang, Jason A. Stavropoulos, Kresna Hartandi, Amanda L. Niquette, Nirupama Soni, Eric F. Johnson, J. Owen McCall, Jennifer J. Bouska, Yanping Luo, Cherrie K. Donawho, Yujia Dai, Patrick A. Marcotte, Keith B. Glaser, Michael R. Michaelides, Steven K. Davidsen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (4): 995–1006.
https://doi.org/10.1158/1535-7163.MCT-05-0410
Published: 28 April 2006
View article titled, Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor
Open the PDF for Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor in another window